Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
FEATURED COMPANIES
- Bayer AG
- Biogen Idec, Inc.
- CSL Behring LLC
- F. Hoffmann-La Roche AG
- Grifols SA
- Novo Nordisk A/S
Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Global Haemophilia Treatment Market was valued at USD13906.45 million in 2020 and is forecast to reach USD24205.39 million in 2026 by registering a CAGR of 9.06% during the forecast period. The Global Haemophilia Treatment Market is driven by increasing awareness campaigns regarding haemophilia among the population across the globe. Moreover, ongoing attempts in research and development activities for the development of new therapy solutions is positively impacting the growth of the market. Also, surging incidences of bleeding disorders have been observed worldwide, which is further expected to bolster the growth of market over the next few years.
The Global Haemophilia Treatment Market is segmented based on type, product, treatment, therapy, company and region. Based on type, the market can be categorized into Haemophilia A, Haemophilia B and Haemophilia C. Generally, the classification depends on the deficiency of coagulation factor present in a patient. Based on that, type A is the most frequent type, and the prevalence rate has been recorded to be four times more than haemophilia type B. In addition to this, majority of existing products are used for treating type A haemophilia, which is contributing to the increasing growth of the segment over the coming years.
Regionally, the market is segregated into North America, Europe, Asia- Pacific, South America and Middle East and Africa. Out of which, North America dominated the Global Haemophilia Treatment Market in 2020 owing to increased prevalence of haemophilia A & B in the United States and Canada. Besides this, organic and inorganic strategies of major pharmaceutical companies present in the United States is further contributing to the market growth in the region. Additionally, Asia Pacific region is expected to grow at the fastest rate in the coming years. This high growth can be ascribed to the ease of regulatory policies in Australia and Japan for the approval of drugs for the treatment of haemophilia A. In addition to this, improved funding by public and private players for the improvisation of healthcare facilities in India and China, is further anticipated the drive the market growth in Asia Pacific.
Major players operating in the Global Haemophilia Treatment Market include Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, Pfizer, Inc., Takeda Pharmaceutical Company, Sanofi S.A., CSL Behring LLC, BioMarin Pharmaceutical Inc., Octapharma AG, Sangamo Therapeutics Inc., Eagle Pharmaceuticals Inc., Baxter International, Inc., Grifols SA, Biogen Idec, Inc., Alnylam Pharmaceuticals Inc., and others. The companies are adopting new strategies in order to stay competitive in the market. Rising competitiveness is anticipated to drive innovation in the market, therefore helping the industry to solve existing challenges and meet the unmet needs in the market. Besides, these major market players are focusing on new product development, mergers and acquisitions, and business expansion to attain a higher market share.
Years considered for this report:
- Historical Years: 2016-2019
- Base Year: 2020
- Estimated Year: 2021
- Forecast Period: 2022-2026
Objective of the Study:
- To analyze the historical growth in the market size of the Global Haemophilia Treatment Market from 2016 to 2020.
- To estimate and forecast the market size of the Global Haemophilia Treatment Market from 2021 to 2026 and growth rate until 2026.
- To classify and forecast the Global Haemophilia Treatment Market based on type, product, treatment, therapy, company and regional distribution.
- To identify dominant region or segment in the Global Haemophilia Treatment Market.
- To identify drivers and challenges for the Global Haemophilia Treatment Market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Global Haemophilia Treatment Market.
- To conduct pricing analysis for the Global Haemophilia Treatment Market.
- To identify and analyze the profile of leading players operating in the Global Haemophilia Treatment Market.
- To identify key sustainable strategies adopted by market players in the Global Haemophilia Treatment Market.
The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of companies across the globe. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the manufacturers which could not be identified due to the limitations of secondary research. The publisher analyzed the hospitals/labs and presence of all major players across the globe.
The publisher calculated the market size of the Global Haemophilia Treatment Market by using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.
Key Target Audience:
- Haemophilia treatment facilities, companies and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, forums and alliances related to haemophilia treatment
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end-users, etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.
Report Scope:
In this report, the Global Haemophilia Treatment Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Global Haemophilia Treatment Market, By Type:
- Haemophilia A
- Haemophilia B
- Haemophilia C
Global Haemophilia Treatment Market, By Product:
- Recombinant Coagulation Factor Concentrates
- Plasma Derived Coagulation Factor Concentrate
- Desmopressin
- Antifibrinolytics Agents
Global Haemophilia Treatment Market, By Treatment:
- On-demand
- Prophylaxis
Global Haemophilia Treatment Market, By End-user:
- Replacement Therapy
- ITI therapy
- Gene Therapy
Global Haemophilia Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Asia-Pacific
- India
- China
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Haemophilia Treatment Market.
Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs.
What is the estimated value of the Global Haemophilia Treatment Market?
What is the growth rate of the Global Haemophilia Treatment Market?
What is the forecasted size of the Global Haemophilia Treatment Market?
Who are the key companies in the Global Haemophilia Treatment Market?
FEATURED COMPANIES
- Bayer AG
- Biogen Idec, Inc.
- CSL Behring LLC
- F. Hoffmann-La Roche AG
- Grifols SA
- Novo Nordisk A/S
List of Figures
A selection of companies mentioned in this report includes:
- Novo Nordisk A/S
- F. Hoffmann-La Roche AG
- Bayer AG
- Pfizer, Inc.
- Takeda Pharmaceutical Company
- Sanofi S.A.
- CSL Behring LLC
- BioMarin Pharmaceutical Inc.
- Octapharma AG
- Sangamo Therapeutics Inc.
- Eagle Pharmaceuticals Inc.
- Baxter International, Inc.
- Grifols SA
- Biogen Idec, Inc.
- Alnylam Pharmaceuticals Inc.